Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased.

Diebold, Matthias; Locher, Eleonore; Boide, Philipp; Enzler-Tschudy, Annette; Faivre, Anna; Fischer, Ingeborg; Helmchen, Birgit; Hopfer, Helmut; Kim, Min Jeong; Moll, Solange; Nanchen, Giliane; Rotman, Samuel; Saganas, Charalampos; Seeger, Harald; Kistler, Andreas D (2022). Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased. Kidney international, 102(6), pp. 1409-1419. Elsevier 10.1016/j.kint.2022.08.021

[img] Text
1-s2.0-S0085253822006974-main.pdf - Accepted Version
Restricted to registered users only until 9 September 2023.
Available under License Publisher holds Copyright.

Download (3MB) | Request a copy

Numerous cases of glomerulonephritis manifesting shortly after SARS-CoV-2 vaccination have been reported, but causality remains unproven. Here, we studied the association between mRNA-based SARS-CoV-2 vaccination and new-onset glomerulonephritis using a nationwide retrospective cohort and a case-cohort design. Data from all Swiss pathology institutes processing native kidney biopsies served to calculate incidence of IgA nephropathy, pauci-immune necrotizing glomerulonephritis, minimal change disease and membranous nephropathy in the adult Swiss population. The observed incidence during the vaccination campaign (January to August 2021) was not different from the expected incidence calculated using a Bayesian model based on the years 2015 to 2019 (incidence rate ratio 0.86, 95%-credible interval 0.73 -1.02) and did not cross the upper boundary of the 95% credible interval for any month. Among 111 patients 18 years and older with newly diagnosed glomerulonephritis between January and August 2021, 38.7% had received at least one vaccine dose before biopsy, compared to 39.5% of the general Swiss population matched for age and calendar-time. The estimated risk ratio for the development of new-onset biopsy-proven glomerulonephritis was not significant at 0.97 (95%-confidence interval 0.66-1.42) in vaccinated vs. unvaccinated individuals. Patients with glomerulonephritis manifesting within four weeks after vaccination did not differ clinically from those manifesting temporally unrelated to vaccination. Thus, vaccination against SARS-CoV-2 was not associated with new-onset glomerulonephritis in these two complementary studies with most temporal associations between SARS-CoV-2 vaccination and glomerulonephritis likely coincidental.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology > Clinical Pathology
04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Saganas, Charalampos

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1523-1755

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

14 Sep 2022 14:00

Last Modified:

05 Dec 2022 16:24

Publisher DOI:

10.1016/j.kint.2022.08.021

PubMed ID:

36096267

Uncontrolled Keywords:

COVID-vaccine Editor’s Note Glomerulonephritis IgA nephropathy SARS-CoV-2 vaccination membranous nephropathy minimal change disease

BORIS DOI:

10.48350/172880

URI:

https://boris.unibe.ch/id/eprint/172880

Actions (login required)

Edit item Edit item
Provide Feedback